<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02070822</url>
  </required_header>
  <id_info>
    <org_study_id>201012077RB</org_study_id>
    <nct_id>NCT02070822</nct_id>
  </id_info>
  <brief_title>3T MRI to Predict TACE Response of HCC</brief_title>
  <official_title>Combination of Dynamic Contrast-enhanced and Diffusion-weighted Imaging and Magnetic Resonance Spectroscopy in 3T MRI to Early Predict Treatment Efficacy in Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective clinical study using DCE-MRI, DWI and MRS in 3T scanner to&#xD;
      evaluate tumors in patients with unresectable HCC after TACE. A total of 100 subjects will be&#xD;
      recruited. MRI will be performed before TACE (day 0), day 14, and day 28 to assess the tumor&#xD;
      responses. After day 28, all subjects will receive standard clinical care and be follow-up&#xD;
      for 1 year. The imaging parameters will be compared among each MRI and correlate with&#xD;
      patients' outcome. The investigators hypothesis that it might be helpful to combine DCE-MRI,&#xD;
      DWI, and MRS for assessment of tumor response after TACE and predict patients' prognosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a non-invasive quantitative&#xD;
      technique for assessing micro-vascular structure by tracking the pharmacokinetics of injected&#xD;
      low-molecular weight contrast agents as they pass through the tumor vasculature. This&#xD;
      modality is being increasingly used in many oncological studies to characterize tumor&#xD;
      angiogenesis and invasiveness, and monitor the treatment response.&#xD;
&#xD;
      Diffusion-weighted imaging (DWI) enables qualitative and quantitative assessment of tissue&#xD;
      diffusivity (apparent diffusion coefficient, ADC) without the use of gadolinium chelates. DWI&#xD;
      has been suggested to be useful in monitoring the response of HCC after TACE because of&#xD;
      earlier assessment of tumor necrosis with increasing ADC values.&#xD;
&#xD;
      MR spectroscopy facilitates the study of cellular metabolism and in vivo detection of&#xD;
      abnormalities. A few studies of in vivo MR spectroscopy reported an increase in choline&#xD;
      levels within tumors such as HCC and a reduction in the lipid-to-choline ratio after&#xD;
      conventional TACE was performed for HCC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>tumor response</measure>
    <time_frame>change of tumor size from baseline to at 6 months</time_frame>
    <description>change of tumor size from baseline to at 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change of baseline MRI parameters</measure>
    <time_frame>change of MRI parameters from baseline to at 6 months</time_frame>
    <description>comparsion of MRI parameters from baseline to 6 months</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <arm_group>
    <arm_group_label>TACE patients, for HCC</arm_group_label>
    <description>unresectable HCC patients</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Hospital patients, admitted for TACE treatment of HCC&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Prior Informed Consent Form&#xD;
&#xD;
          2. Patients who had undergone surgery for the treatment of HCC are allowed.&#xD;
&#xD;
          3. At least one measurable tumor, according to RECIST version 1.1.&#xD;
&#xD;
          4. Age more than 20 years.&#xD;
&#xD;
          5. ECOG performance status 0 or 1.&#xD;
&#xD;
          6. Life expectancy more than 3 months.&#xD;
&#xD;
          7. Child-Pugh class A.&#xD;
&#xD;
          8. Unresectable, multinodular tumors&#xD;
&#xD;
          9. Confirmed Diagnosis of HCC&#xD;
&#xD;
         10. At least one uni-dimensional lesion measurable according to the Modified RECIST&#xD;
             criteria by MRI&#xD;
&#xD;
         11. Adequate bone marrow, liver and renal function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of TACE&#xD;
&#xD;
          2. Diffuse infiltrative HCC or presence of main portal vein invasion or extrahepatic&#xD;
             metastasis&#xD;
&#xD;
          3. Any contraindications for hepatic embolization procedures:, including hepatofugal&#xD;
             blood flow, large intrahepatic or porto-systemic shunt, impaired clotting test, renal&#xD;
             failure requiring hemo-or peritoneal dialysis&#xD;
&#xD;
          4. Any contraindication for MRI, including known contrast allergy, electronically&#xD;
             operated implants or devices, and claustrophobia.&#xD;
&#xD;
          5. Other acute or chronic medical, psychiatric condition, or laboratory abnormality that&#xD;
             may increase the risk associated with study participation and is inappropriate for&#xD;
             this study by the judgment of the investigator&#xD;
&#xD;
          6. Known history of HIV infection&#xD;
&#xD;
          7. Concurrent primary extrahepatic cancer&#xD;
&#xD;
          8. Pregnant or breast-feeding subjects&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bang-Bin Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan Uinversity Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bang-Bin Chen, MD</last_name>
    <email>bangbin@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan Uinversity Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bang-Bin Chen, MD</last_name>
      <email>bangbin@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Bang-Bin Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>January 2, 2012</study_first_submitted>
  <study_first_submitted_qc>February 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2014</study_first_posted>
  <last_update_submitted>February 23, 2014</last_update_submitted>
  <last_update_submitted_qc>February 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatocellular carcinoma</keyword>
  <keyword>Transarterial chemoembolization</keyword>
  <keyword>Magnetic resonance imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

